Latest

Inside Life Sciences
Issue 1

CMA scrutinises de-branding of generics

On 7 December 2016, the Competition and Markets Authority announced its finding that pharmaceutical manufacturer Pfizer Limited and its distributor Flynn Pharma Limited had abused their respective dominant positions by imposing unfair prices for an anti-epilepsy drug.

Increased enforcement activity by the CMA – what does this mean for you?

Back in February 2016, the National Audit Office ("NAO") criticised the lack of successful enforcement activity by the Competition and Markets Authority ("CMA").

SPCs: uncertainty continues with two more references to the CJEU

On 13 January 2017, Arnold J made two references to the European Court of Justice in relation to the Supplementary Protection Certificate Regulation, one concerning SPCs for combination products, the other new formulations of old active ingredients.

Patents Court finds triple combination SPC for HIV-1 treatment Atripla invalid

Following his decision to refer questions to the Court of Justice of the European Union relating to the SPC for Gilead's Truvada product, Arnold J has decided, in the light of the relevant claim in the basic Patent, that the SPC for the triple combination product Atripla (marketed by Gilead and Bristol-Myers Squibb) is invalid.

Patents Court grants ground-breaking declarations in Humira dosage regimen case

In the latest instalment in the battle concerning AbbVie's 'Humira' product (the highest-selling prescription drug in the world by global sales), Mr Justice Henry Carr has ordered declarations in favour of Fujifilm and Samsung Bioepsis/Biogen.

Insuring innovation in life sciences

Life sciences companies are increasingly relying on technology to innovate and shape their working methods.

Brexit: the Impact on the Life Sciences Industry

Following the referendum vote that the UK should leave the EU, the political landscape has been fast developing.